Integrated CUPED + GSD + Bayesian
NSCLC immunotherapy combination: Phase II → Phase III development
$14.1M
Total Savings
16 mo
Earlier BLA
$2.1B
NPV Gain
11,750×
ROI
Scenario
A pharmaceutical company was developing a novel immunotherapy combination for first-line treatment of non-small cell lung cancer (NSCLC). The development program included a signal-finding Phase II trial followed by a pivotal Phase III.
The question: Could all three efficient design methodologies be applied across the development program for compounding benefits?
Integrated Methodology
Phase II: CUPED
Baseline tumor burden and PD-L1 expression used as covariates for the primary endpoint analysis (objective response rate).
Result: 40% sample size reduction (80 → 53 patients)
Phase II → III Transition: Bayesian
Bayesian predictive probability computed from Phase II results to quantify Phase III success likelihood.
Result: 85% probability of achieving Phase III primary endpoint (PFS HR ≤ 0.75)
Phase III: Group Sequential
4-look O'Brien-Fleming design with non-binding futility boundaries for the progression-free survival (PFS) endpoint.
Result: Expected sample size reduction of 15% (500 → 425 expected)
Program Comparison
| Program Element | Traditional | Zetyra-Optimized | Savings |
|---|---|---|---|
| Phase II | 80 patients, 12 mo, $4.0M | 53 patients, 8 mo, $2.4M | $1.6M (40%) |
| Phase III | 500 patients, 54 mo, $100M | 425 expected, 42 mo, $87.5M | $12.5M (13%) |
| Total Program | 66 months, $104M | 50 months, $89.9M | $14.1M (14%) |
| BLA Submission | Month 72 | Month 56 | 16 months earlier |
Revenue Impact
For a successful NSCLC immunotherapy with $2 billion peak annual sales, the 16-month acceleration in market entry generates:
- $2.67 billion additional revenue over product lifecycle
- $2.1 billion NPV (at 10% discount rate)
- Extended patent-protected sales period
11,750×
ROI per program
$14.1M savings / $1.2K subscription
Why Integration Matters
Using all three methodologies creates compounding benefits:
CUPED in Phase II
Smaller, faster Phase II means earlier Phase III start. The 4-month acceleration at Phase II compounds throughout the program.
Bayesian Go/No-Go
Quantitative Phase III probability enables confident investment decisions. Avoid wasting $50-100M on Phase III programs destined to fail.
GSD in Phase III
Early stopping for efficacy or futility reduces expected duration and cost. For a successful drug, this accelerates market entry even further.
Timeline Comparison
Traditional Development
Month 72: BLA Submission
Zetyra-Optimized
Month 56: BLA Submission
Ready to optimize your development program?
Access all three calculators with a single Zetyra subscription.